In summary, our study identifies an important PTM, CD147‐K148me2, in NSCLC and reveals the role of CD147‐K148me2‐mediated intercellular crosstalk in NSCLC immunosuppression and progression, suggesting that targeting CD147‐K148me2 is a potential interventional strategy for NSCLC therapy. Here, BSG is linked to non-small cell lung carcinoma.